MedPath
Found 203 clinical trials|View Analysis
Sort by:

Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma

Phase 2
Recruiting
Conditions
Asthma
Interventions
Drug: Lunsekimig
Drug: Short-Acting Beta Agonists (SABA)
Drug: Placebo
Drug: Fluticasone/salmeterol
Drug: Budesonide/formoterol
First Posted Date
2024-11-06
Last Posted Date
2024-12-13
Lead Sponsor
Sanofi
Target Recruit Count
1000
Registration Number
NCT06676319
Locations
🇺🇸

Clinical Research Associates of Central PA - Dubois- Site Number : 8400013, DuBois, Pennsylvania, United States

🇨🇦

Investigational Site Number : 1240002, Sherbrooke, Quebec, Canada

🇬🇧

Investigational Site Number : 8260005, Barnsley, United Kingdom

and more 5 locations

Efficacy and Safety Study of Fluticasone/Salmeterol Administered With Elpenhaler

Not Applicable
Completed
Conditions
Asthma
Interventions
Device: RP - TA
First Posted Date
2022-07-14
Last Posted Date
2022-09-10
Lead Sponsor
Elpen Pharmaceutical Co. Inc.
Target Recruit Count
42
Registration Number
NCT05459194

Replication of the INSPIRE Trial in Healthcare Claims Data

Completed
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Drug: salmeterol-fluticasone
Drug: Tiotropium
First Posted Date
2022-01-05
Last Posted Date
2023-07-27
Lead Sponsor
Brigham and Women's Hospital
Target Recruit Count
98278
Registration Number
NCT05179512
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With Asthma

Phase 4
Completed
Conditions
Asthma
Interventions
Drug: Fluticasone propionate/salmeterol (FS)
Drug: Standard of Care Asthma Medication
Drug: Standard of Care Rescue Medication
Drug: Albuterol
First Posted Date
2020-12-21
Last Posted Date
2023-03-14
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Target Recruit Count
427
Registration Number
NCT04677959
Locations
🇺🇸

Teva Investigational Site 14974, Fountain Valley, California, United States

🇺🇸

Teva Investigational Site 14982, Los Angeles, California, United States

🇺🇸

Teva Investigational Site 14955, Fort Lauderdale, Florida, United States

and more 43 locations

Mechanisms of Adverse Effects of Long-Acting Beta-Agonists in Asthma

Phase 4
Recruiting
Conditions
Asthma
Interventions
First Posted Date
2020-08-07
Last Posted Date
2023-04-25
Lead Sponsor
Imperial College London
Target Recruit Count
24
Registration Number
NCT04503460
Locations
🇬🇧

St Mary's Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom

A Bioequivalence Study Between Fluticasone and Salmeterol vs. SERETIDE DISKUS® in Healthy Volunteers With Charcoal Blockade

Phase 1
Completed
Conditions
Bioequivalence
Interventions
Drug: Reference Product (SERETIDE DISKUS® 100/50 inhalation powder/GSK)
Drug: Test Product (Fluticasone propionate and salmeterol xinafoate inhalation powder/Respirent Pharmaceuticals)
Other: Activated Charcoal suspension
First Posted Date
2019-10-11
Last Posted Date
2020-07-07
Lead Sponsor
Respirent Pharmaceuticals Co Ltd.
Target Recruit Count
36
Registration Number
NCT04124094
Locations
🇬🇷

BECRO Clinical Facility, Larissa, Thessaly, Greece

A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. SERETIDE DISKUS® in Healthy Volunteers With Charcoal Blockade (BREATH-PK250-CC)

Phase 1
Completed
Conditions
Bioequivalence
Interventions
Drug: Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg inhalation powder/Respirent Pharmaceuticals
Drug: SERETIDE DISKUS® 250/50 inhalation powder/GSK
Other: Activated Charcoal suspension
First Posted Date
2019-03-28
Last Posted Date
2019-06-05
Lead Sponsor
Respirent Pharmaceuticals Co Ltd.
Target Recruit Count
36
Registration Number
NCT03894280
Locations
🇬🇷

BECRO Clinical Facility, Larissa, Thessaly, Greece

A Retrospective rEal-life daTa Study to Assess the exaceRbations and Lung functIon in Chronic Obstructive Pulmonary Disease ( COPD ) patiEnts receiVing Fluticasone/Salmeterol Comparing to Those Εscalating in Open-triple Fluticasone/Salmeterol, Long Acting Muscarinic Antagonist (LAMA) Combination

Completed
Conditions
COPD
COPD Exacerbation
First Posted Date
2019-02-28
Last Posted Date
2024-02-20
Lead Sponsor
Elpen Pharmaceutical Co. Inc.
Target Recruit Count
1000
Registration Number
NCT03858348
Locations
🇬🇷

Papanikolaou Hospital of Thessaloniki, Thessaloniki, Greece

Salmeterol/Fluticasone Easyhaler in the Treatment of Asthma and COPD

Completed
Conditions
Chronic Obstructive Pulmonary Disease
Asthma
First Posted Date
2018-11-28
Last Posted Date
2020-02-28
Lead Sponsor
Orion Corporation, Orion Pharma
Target Recruit Count
231
Registration Number
NCT03755544
Locations
🇩🇪

Lungenpraxis, Hamburg, Germany

Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salmeterol Inhalation Powder in Subjects With Asthma

Phase 3
Completed
Conditions
Asthma
Interventions
First Posted Date
2018-11-28
Last Posted Date
2021-09-24
Lead Sponsor
Actavis Inc.
Target Recruit Count
999
Registration Number
NCT03756883
Locations
🇺🇸

Study Site 101, Miami Lakes, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath